



The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

Drug Advisory Committee July 2024 Meeting Outcome

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection¹
1	Asciminib	Scemblix	Malignant disease and immunosuppression	Approved	
2	Azacitidine	Onureg	Malignant disease and immunosuppression	Approved	
3	Bevacizumab	Mvasi	Malignant disease and immunosuppression	Approved	
4	Capmatinib	Tabrecta	Malignant disease and immunosuppression	Approved	
5	Carbomer Eye Gel	Liposic Eye Gel	Eye	Approved	
6	Carglumic acid	Carbaglu	Nutrition and blood	Pending	Pending further information
7	Dapagliflozin	Forxiga	Endocrine system	Approved	
8	Eptinezumab	Vyepti	Central nervous system	Rejected	Alternative(s) available in HADF with comparable benefits
9	Fluticasone / umeclidinium / vilanterol	Trelegy Ellipta	Respiratory system	Approved	
10	Fruquintinib	Elunate	Malignant disease and immunosuppression	Approved	
11	Glecaprevir/Pibrentasvir	Maviret	Infections	Approved	
12	Glofitamab	Columvi	Malignant disease and immunosuppression	Pending	Pending further information
13	Golimumab	Simponi	Musculoskeletal and joint disease	Rejected	Alternative(s) available in HADF with comparable benefits
14	Inclisiran	Leqvio	Cardiovascular system	Approved	
15	L-arginine hydrochloride L-lysine hydrochloride	LysaKare	Nutrition and blood	Approved	
16	Lutetium 177 vipivotide tetraxetan	Pluvicto	Radiopharmaceuticals	Approved	
17	Lutetium oxodotreotide	Lutathera	Radiopharmaceuticals	Approved	

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection¹
18	Mavacamten	Camzyos	Cardiovascular system	Approved	
19	Ocrelizumab	Ocrevus	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
20	Olaparib	Lynparza	Malignant disease and immunosuppression	Pending	Pending further information
21	Oxycodone	OxyNorm	Central nervous system	Approved	
22	Pembrolizumab	Keytruda	Malignant disease and immunosuppression	Approved	
23	Pertuzumab / Trastuzumab	Phesgo	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
24	Ravulizumab	Ultomiris	Central nervous system	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
25	Riluzole	Rilutek	Central nervous system	Approved	
26	Rimegepant	Nurtec	Central nervous system	Approved	
27	Sacituzumab govitecan	Trodely	Malignant disease and immunosuppression	Pending	Pending further information
28	Selinexor	Xpovio	Malignant disease and immunosuppression	Pending	Pending further information
29	Silodosin	Urief	Obstetrics, gynaecology, and urinary-tract disorders	Rejected	Alternative(s) available in HADF with comparable benefits
30	Sofosbuvir/Velpatasvir	Epclusa	Infections	Approved	
31	Tafamidis	Vyndamax	Cardiovascular system	Pending	Pending further information
32	Tofacitinib	Xeljanz	Musculoskeletal and joint disease	Approved	
33	Zanubrutinib	Brukinsa	Malignant disease and immunosuppression	Approved	

¹ The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.